PEERJ 润色咨询

PeerJ

出版年份:暂无数据 年文章数:15548 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:6.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-08-24 ms7000002977722170 来自北京

    审稿速度:3.0
    经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。
    期间我没有催稿,一直等(没报太大希望)。
    总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。
    最终竟然被接收了。
    据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。
    所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-04-29 羽翼纷飞 来自重庆

    偏重的研究方向:回顾性
    经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑

    16

    展开16条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2026-01-14 icesunnyli 来自北京

    偏重的研究方向:生信分析
    经验分享:是的,我是12.26号投稿,1.13号通过checking#期刊论坛#,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-11-28 ms9000002043574227 来自山东省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤免疫
    经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-04-27 ms4000000419149541 来自四川省

    请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-12-19 匿名用户

    不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature.

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-11-17 ms3000001402508056 来自云南省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:临床;回顾性
    经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-11-07 ms6000001146630729 来自湖北省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:meta-analysis;临床
    经验分享:今年5月6投,7.20大修,8.29小修,10月31接受

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-08-18 cyz01 来自重庆

    偏重的研究方向:炎症;回顾性研究
    经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2278542, encodeId=f61022e854240, content=审稿速度:3.0<br>经验分享:投稿10天后被送审,等了差不多 2 个月才有消息。<br>期间我没有催稿,一直等(没报太大希望)。<br>总共说邀请了 2 位编辑,给了一些修改意见,又进一步优化润色了一翻。<br>最终竟然被接收了。<br>据我所知,像用传统模型却没结合 AI 优化;临床研究若缺少伦理审批(IRB 批号),也容易被拒。<br>所以大家投稿前一定要研究一下投稿指南,确保研究符合这些要求。​<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Sun Aug 24 17:13:04 CST 2025, time=2025-08-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262703, encodeId=0fc32262e037a, content=偏重的研究方向:回顾性<br>经验分享:4月15号投稿,4月29号通过check,2周通过check,目前在找责任编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/eaf6a670992538bfff9986e52fed6975.jpg, createdBy=10022477991, createdName=羽翼纷飞, createdTime=Tue Apr 29 09:01:05 CST 2025, time=2025-04-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2297080, encodeId=f113229e080c4, content=偏重的研究方向:生信分析<br>经验分享:是的,我是12.26号投稿,1.13号通过checking<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>,让,我补充一些资料,重新提交,之后说是送审,希望一切顺利,早日接受成功,这杂志原始数据啥的要求挺多,挺麻烦,但也挺正规的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b6e2772389, createdName=icesunnyli, createdTime=Wed Jan 14 05:45:56 CST 2026, time=2026-01-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2291050, encodeId=12462291050da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:8.1首次提交;8.6 passed checks;8.14 分配学术编辑;9.25 First decision;10.16 一修返回+交版面费;10.24 再次修改;11.4 pass checks。到现在11.23一直是in review。在first decision的时候就可以交版面费了,已经交上了,现在有点好奇到底是接收了还是没接收。。有没有有经验的小伙伴解惑。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81198147933, createdName=ms9000002043574227, createdTime=Fri Nov 28 18:18:33 CST 2025, time=2025-11-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2262442, encodeId=f59c226244211, content=请问要所有作者确认之后,才能分配编辑吗,因为我在系统上填的作者顺序和手稿的不一样xiangixugia,想修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5289245186, createdName=ms4000000419149541, createdTime=Sun Apr 27 09:02:07 CST 2025, time=2025-04-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2293867, encodeId=5853229386ea5, content=不收无实验的MR:Mendelian randomisation studies will only be considered if their findings are confirmed experimentally, and described and analysed in the same submission (see https://peerj.com/about/policies-and-procedures/#discipline-standards). In addition, such studies must not duplicate other similar publications and must make a meaningful contribution to the literature., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Dec 19 15:03:14 CST 2025, time=2025-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2289263, encodeId=1b06228926334, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:临床;回顾性<br>经验分享:请问这个杂志不能走对公支付吗,没有invoice,支付宝不给报账, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89469113, createdName=ms3000001402508056, createdTime=Mon Nov 17 22:52:28 CST 2025, time=2025-11-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2287992, encodeId=c63a228e99200, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:meta-analysis;临床<br>经验分享:今年5月6投,7.20大修,8.29小修,10月31接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7f9509814, createdName=ms6000001146630729, createdTime=Fri Nov 07 12:54:25 CST 2025, time=2025-11-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2277740, encodeId=10d622e7740aa, content=偏重的研究方向:炎症;回顾性研究<br>经验分享:6.12提交,6.28check,今天8.18还是Reviewing,等待中……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=051e2959338, createdName=cyz01, createdTime=Mon Aug 18 22:25:11 CST 2025, time=2025-08-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2262940, encodeId=68de2262940fc, content=请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99666213085, createdName=62260_8740, createdTime=Wed Apr 30 21:21:48 CST 2025, time=2025-04-30, status=1, ipAttribution=河北省)]
    2025-04-30 62260_8740 来自河北省

    请问一下投过的同胞们 这个隶属机构没有我的单位怎么填的,复制粘贴又不行,非得选一个机构才能点别的

    0

共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分